Related Experiment Video

Updated: Jul 19, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Treatment options for multidrug-resistant bacteria

Helen Giamarellou1

  • 14th Department of Internal Medicine, University General Hospital ATTIKON, 1 Rimini Street, 124 64 Athens, Greece. hgiama@ath.forthnet.gr

Expert Review of Anti-Infective Therapy
|October 3, 2006
PubMed

Insights

Multidrug-resistant bacterial infections are a global threat. With limited new antibiotics, especially against Pseudomonas aeruginosa, current strategies focus on judicious use of existing drugs and infection control.

Area of Science:

  • * Infectious Diseases
  • * Microbiology
  • * Pharmacology

Background:

  • * Nosocomial infections caused by multidrug-resistant bacteria (MDRB) pose a significant global health challenge.
  • * There is a critical lack of novel antimicrobial agents effective against key MDRB pathogens like Pseudomonas aeruginosa.
  • * Existing antibiotics such as linezolid, newer glycopeptides, daptomycin, and tigecycline show activity against specific MDRB strains (MRSA, VRE, Acinetobacter baumannii, ESBL+ Enterobacteriaceae).

Purpose of the Study:

  • * To review the current landscape of antimicrobial agents and strategies for combating multidrug-resistant bacterial infections.
  • * To highlight the challenges posed by pathogens like Pseudomonas aeruginosa and the limited therapeutic options.
  • * To emphasize the role of colistin as a rediscovered agent and the importance of infection control measures.

Main Methods:

  • * Review of existing literature on multidrug-resistant bacteria and antimicrobial therapies.
  • * Analysis of the efficacy and limitations of currently available and investigational antibiotics.
  • * Discussion of the clinical application and outcomes of colistin in treating infections caused by MDRB.

Main Results:

  • * Limited development of new antibiotics targeting major nosocomial pathogens like Pseudomonas aeruginosa.
  • * Colistin, an older antibiotic, has been repurposed for treating infections caused by ESBL-producing Enterobacteriaceae, multidrug-resistant P. aeruginosa, and Acinetobacter baumannii, with reported success rates of 50-73% in retrospective studies.
  • * Immunostimulatory approaches for Staphylococcus aureus infections are still in early development stages.

Conclusions:

  • * The stagnation in antibiotic research and development necessitates a focus on optimizing the use of existing antimicrobial agents.
  • * Strict infection control protocols are paramount in preventing and managing the spread of multidrug-resistant bacterial infections.
  • * Rational antibiotic prescribing policies are crucial in the fight against nosocomial infections caused by MDRB.

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System05:06

Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antibiotic Selection00:57

Antibiotic Selection

Overview